|

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

RECRUITINGPhase 2Sponsored by Peter Siesjö
Actively Recruiting
PhasePhase 2
SponsorPeter Siesjö
Started2024-10-07
Est. completion2026-10
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07364786

Summary

The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are: * Will Salovum® reduce intratumoral pressure? * Will Salovum® influence the release of inflammatory cytokines from tumor tissue? Additionally, the study will investigate the impact of Salovum® on intratumoral partial oxygen pressure and tumor volume. Researchers will: * Place probes for measuring intratumoral pressure, microdialysis, and partial oxygen pressure during a standard biopsy procedure. * Compare measurements from participants before and during ingestion of Salovum®. Participants will: * Have probes implanted during a surgical biopsy. * Ingest Salovum® 24 to 72 hours after the procedure.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Suspected glioblastoma
2. Age 18-75 years
3. Planned diagnostic biopsy
4. Informed consent of subject

Exclusion Criteria:

1\. Known egg yolk allergy

Conditions2

CancerGlioblastoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.